

Konstantinos Stavropoulos

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/5052600/konstantinos-stavropoulos-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

589
citations

12
h-index

20
g-index

92
ext. papers

805
ext. citations

5.8
avg, IF

4.39
L-index

#	Paper	IF	Citations
79	Diabetes and lipid metabolism. <i>Hormones</i> , 2018 , 17, 61-67	3.1	81
78	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2018 , 16, 246-253	3.3	49
77	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , 2018 , 16, 130-142	3.3	36
76	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 249-253	5.5	30
75	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. <i>Current Hypertension Reports</i> , 2020 , 22, 90	4.7	22
74	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2018 , 24, 4587-4592	3.3	18
73	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 572-584	2.3	17
72	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. <i>Journal of Human Hypertension</i> , 2020 , 34, 764-767	2.6	16
71	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. <i>Open Cardiovascular Medicine Journal</i> , 2018 , 12, 29-40	0.7	15
70	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 562-571	2.3	14
69	Hypertension in Metabolic Syndrome: Novel Insights. <i>Current Hypertension Reviews</i> , 2020 , 16, 12-18	2.3	14
68	Testosterone Treatment in Older Men. <i>New England Journal of Medicine</i> , 2016 , 375, 90	59.2	13
67	Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2018 , 378, 967-968	59.2	12
66	Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome. <i>Gynecological Endocrinology</i> , 2018 , 34, 1019-1021	2.4	12
65	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. <i>Current Pharmaceutical Design</i> , 2017 , 23, 1510-1521	3.3	12
64	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. <i>Current Pharmaceutical Design</i> , 2017 , 23, 1540-1550	3.3	12
63	Now That Renal Denervation Works, How Do We Proceed?. <i>Circulation Research</i> , 2019 , 124, 693-695	15.7	11

62	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. <i>Current Pharmaceutical Design</i> , 2018 , 24, 1879-1886	3.3	11
61	The potential role of statins in treating liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 331-339	4.2	10
60	Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis. <i>Current Vascular Pharmacology</i> , 2018 , 16, 239-245	3.3	10
59	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. <i>Current Clinical Pharmacology</i> , 2018 , 13, 261-272	2.5	10
58	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2019 , 158, 107927	7.4	10
57	Update of the position paper on arterial hypertension and erectile dysfunction. <i>Journal of Hypertension</i> , 2020 , 38, 1220-1234	1.9	9
56	The effect of SGLT2 inhibitors on cardiovascular events and renal function. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1251-1261	3.8	9
55	Hematocrit and Stroke: A Forgotten and Neglected Link?. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 591-598	5.3	8
54	Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 65-68	2.3	8
53	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. <i>Current Vascular Pharmacology</i> , 2021 , 19, 323-342	3.3	8
52	Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia. <i>Current Pharmaceutical Design</i> , 2018 , 24, 3647-3653	3.3	7
51	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus. <i>Vascular Health and Risk Management</i> , 2019 , 15, 365-373	4.4	6
50	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 798-800	2.3	6
49	Treatment strategies for hypertension in patients with type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1241-1252	4	5
48	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 942-948	2.3	5
47	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. <i>Journal of Sexual Medicine</i> , 2019 , 16, 1199-1211	1.1	4
46	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. <i>European Journal of Internal Medicine</i> , 2020 , 77, 153-155	3.9	4
45	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. <i>American Journal of Hypertension</i> , 2016 , 29, 662	2.3	4

44	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. <i>Current Vascular Pharmacology</i> , 2019 , 17, 425-428	3-3	4
43	Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 2502	59-2	4
42	Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. <i>Current Pharmaceutical Design</i> , 2018 , 24, 5508-5516	3-3	4
41	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. <i>Current Vascular Pharmacology</i> , 2018 , 16, 276-288	3-3	4
40	Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 1336-1338	2-3	3
39	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 241-251	4-1	3
38	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , 2020 , 18, 125-138	3-3	3
37	Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 255-257	2-3	3
36	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. <i>Journal of Human Hypertension</i> , 2021 ,	2-6	3
35	The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. <i>Current Pharmaceutical Design</i> , 2018 , 24, 5517-5524	3-3	3
34	Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2018 , 18, 94-103	1-1	3
33	Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 1073	2-3	3
32	Primary Aldosteronism: Novel Insights. <i>Current Hypertension Reviews</i> , 2020 , 16, 19-23	2-3	3
31	Insomnia and hypertension: A misty landscape. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 835-837	2-3	2
30	Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. <i>Journal of Hypertension</i> , 2018 , 36, 701	1-9	2
29	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 634-636	2-3	2
28	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 469-471	2-3	2
27	Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2018 , 18, 104-113	1-1	2

26	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2020 , 125, 887-893	3	2
25	Renal tubular transport protein regulation in primary aldosteronism: can large-scale proteomic analysis offer a new insight?. <i>Journal of Human Hypertension</i> , 2021 , 35, 825-827	2.6	2
24	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2018 , 18, 120-126	1.1	2
23	Blood pressure and cardiovascular outcomes: a closer look. <i>Lancet, The</i> , 2017 , 389, 1295-1296	40	1
22	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 589-591	2.3	1
21	Depression in hypertensive patients: the role of comorbidities. <i>Journal of Hypertension</i> , 2016 , 34, 1441	1.9	1
20	Letter by Stavropoulos et al Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control". <i>Circulation</i> , 2018 , 137, 2664-2665	16.7	1
19	Pharmacological Management of Diabetic Nephropathy. <i>Current Vascular Pharmacology</i> , 2020 , 18, 139-147	1.7	1
18	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. <i>American Journal of Cardiology</i> , 2020 , 137, 133-135	3	1
17	Renin-Angiotensin System Inhibitors: Do They Have the Same Impact at All Ages?. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 828	2.3	1
16	Determinants of pulse wave velocity index and potential implementations. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 1493-1495	2.3	1
15	Antihypertensive drug treatment: the real-life challenge. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 115-117	1.7	1
14	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. <i>Heart Failure Clinics</i> , 2019 , 15, 519-530	3.3	0
13	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 1578-1579	2.3	0
12	Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters. <i>JAMA Internal Medicine</i> , 2017 , 177, 1393	11.5	0
11	The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes. <i>Current Vascular Pharmacology</i> , 2021 , 19, 313-322	3.3	0
10	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. <i>American Journal of Cardiology</i> , 2021 , 138, 116-118	3	0
9	Hypertension in Pregnancy: Unanswered Questions. <i>Current Pharmaceutical Design</i> , 2021 , 27, 3795-3803	3.3	0

8	Impact of Primary Aldosteronism in Resistant Hypertension.. <i>Current Hypertension Reports</i> , 2022 , 1	4.7	o
7	Physical Activity, Fitness, and Sexual Dysfunction 2019 , 373-387		
6	PATHWAY-2: spironolactone for resistant hypertension. <i>Lancet, The</i> , 2016 , 387, 1371-1372	4.0	
5	Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?. <i>Journal of Diabetes and Metabolic Disorders</i> ,1	2.5	
4	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. <i>Clinical and Molecular Hepatology</i> , 2019 , 25, 331-332	6.9	
3	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. <i>Polish Archives of Internal Medicine</i> , 2019 , 129, 648-649	1.9	
2	Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". <i>Circulation</i> , 2016 , 134, e5-6	16.7	
1	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. <i>International Journal of Cardiology: Hypertension</i> , 2019 , 3, 100022	1.6	